Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<ul>
<li>We believe a 1-4-month pullback/consolidation is ongoing, and we would look for an important low to be made near the U.S. election.</li>
<li>Supports to watch continue to be $110 on $ACWI and $41-42 on MSCI EM $EEM, and whether these levels hold or not will determine the severity of the pullback.</li>
<li>Primary reasons for this bearish expectation include major bullish RS inflections for defensive Sectors, and bearish price action in the U.S. (SPX), Japan (TOPIX/Nikkei 225), and Europe (EURO STOXX 50)</li>
</ul>


We believe a 1-4-month pullback/consolidation is ongoing, and we would look for an important low to be made near the U.S. election.
Supports to watch continue to be $110 on $ACWI and $41-42 on MSCI EM $EEM, and whether these levels hold or not will determine the severity of the pullback.
Primary reasons for this bearish expectation include major bullish RS inflections for defensive Sectors, and bearish price action in the U.S. (SPX), Japan (TOPIX/Nikkei 225), and Europe (EURO STOXX 50)


Pullback Continues $ACWI; Stick With Defensives; More Countries With Improving Price and RS Trends

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>Legal and regulatory changes have spawned cannabis companies, focused on cannabis-based medical and recreational products and the development of new breeds of crop </li>
<li>In Cannabis innovations <a href="https://www.smartkarma.com/entities/philip-morris-international" target="_blank" data-smartkarma-citation="entities:13328:1" rel="noopener">Philip Morris International (PM US)</a>, <a href="https://www.smartkarma.com/entities/canopy-growth-corp" target="_blank" data-smartkarma-citation="entities:25083:1" rel="noopener">Canopy Growth (WEED CN)</a>, <a href="https://www.smartkarma.com/entities/jazz-pharmaceuticals-plc" target="_blank" data-smartkarma-citation="entities:15881:1" rel="noopener">Jazz Pharmaceuticals (JAZZ US)</a><a href="https://www.smartkarma.com/entities/merck-co-inc" target="_blank" data-smartkarma-citation="entities:1130:1" rel="noopener">Merck &amp; Co Inc. (MRK US)</a> and <a href="https://www.smartkarma.com/entities/takeda-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:11747:1" rel="noopener">Takeda Pharmaceutical (4502 JP)</a> lead</li>
<li>In overall plant-based extracts innovations <a href="https://www.smartkarma.com/entities/jazz-pharmaceuticals-plc" target="_blank" data-smartkarma-citation="entities:15881:1" rel="noopener">Jazz Pharmaceuticals (JAZZ US)</a>, <a href="https://www.smartkarma.com/entities/eid-parry-india-ltd" target="_blank" data-smartkarma-citation="entities:6925:1" rel="noopener">Eid Parry India (EID IN)</a>, <a href="https://www.smartkarma.com/entities/abbott-laboratories" target="_blank" data-smartkarma-citation="entities:11987:1" rel="noopener">Abbott Laboratories (ABT US), </a>Indena, Mars Incorporated, and Liveleaf are the leaders.</li>
</ul>


Legal and regulatory changes have spawned cannabis companies, focused on cannabis-based medical and recreational products and the development of new breeds of crop 
In Cannabis innovations Philip Morris International (PM US), Canopy Growth (WEED CN), Jazz Pharmaceuticals (JAZZ US)Merck &amp; Co Inc. (MRK US) and Takeda Pharmaceutical (4502 JP) lead
In overall plant-based extracts innovations Jazz Pharmaceuticals (JAZZ US), Eid Parry India (EID IN), Abbott Laboratories (ABT US), Indena, Mars Incorporated, and Liveleaf are the leaders.


Insights from Data Mining Technical Publications - Plant Extracts Including from Cannabis

Market Intelligence, ORTEX

ORTEX Market Intel

Market Intelligence

Global Financial Data and Analytics Platform

ORTEX

ORTEX is a global financial data and analytics platform providing real-time securities lending and short interest data, index rebalance data, holdings and insider transactions, trading signals, corporate actions and news,  stock machine learning and factor scores and other analytics. The majority of the data are downloadable and accessible through APIs.

Equity Bottom-Up

<ul><li>AAPL grabbed the headlines as short interest exploded 130% in a week to 107,942 shares.</li><li>Energy names BP and BTI also drew heavy short attention.</li><li>Borrow markets tightened sharply across several smaller names, with BOT and BLSH seeing costs breach triple digits.</li></ul>

AAPL grabbed the headlines as short interest exploded 130% in a week to 107,942 shares.Energy names BP and BTI also drew heavy short attention.Borrow markets tightened sharply across several smaller names, with BOT and BLSH seeing costs breach triple digits.

Apple Dominates a Busy Week for Short Sellers

India focused: IPO, special situations, Stylus Holdings

Himanshu Dugar

India focused: IPO, special situations

Stylus Holdings

Stylus Holdings is a buy-side equity research firm. We offer bottom-up investment ideas as well as provide on demand equity research and portfolio tracking. 
At Stylus, our focus is to identify market dislocations that can generate 20+% IRR with a reasonable margin of safety. As part of our research process, we do a deep dive into the fundamentals of the company, evaluate their competitive positioning and assess their valuation.
Our investment team is led by Himanshu Dugar. Himanshu is a Chartered Accountant and a CFA charter holder. He has 10+ years of active experience in the stock market with stints at CRISIL Research, a S&P Global copmany and Miras Investments, a single family office based in Dubai.

Equity Research Firm

<ul>
<li>ITC's share prices collapsed on 1st-Jan following a larger-than-expected indirect tax hike on Cigarettes in India. The changes translate to a 20-50% increase in MRP, potentially aiding illicit Cigarette trade.</li>
<li>We present data on how ITC's Cigarette business has performed well despite regular tax hikes and how steep hikes followed by a stable taxation envrionment benefits in the long term.</li>
<li>At CMP, stock is attractive at 20x Cigarette profits alone (peers trade at 25x), offering FMCG and agri business (worth 40/share) + 50k crores in cash/listed investments (40/share) as buffer.</li>
</ul>


ITC's share prices collapsed on 1st-Jan following a larger-than-expected indirect tax hike on Cigarettes in India. The changes translate to a 20-50% increase in MRP, potentially aiding illicit Cigarette trade.
We present data on how ITC's Cigarette business has performed well despite regular tax hikes and how steep hikes followed by a stable taxation envrionment benefits in the long term.
At CMP, stock is attractive at 20x Cigarette profits alone (peers trade at 25x), offering FMCG and agri business (worth 40/share) + 50k crores in cash/listed investments (40/share) as buffer.


ITC - Is It Time for Contrarian Investors to Enter?

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

British American Tobacco / Equity Bottom-Up

<ul><li>British American Tobacco (BAT) presented their 2025 interim results, showing a blend of achievements and challenges that influence the company's future trajectory.</li><li>BAT's revenue rose by 1.8%, and profits from operations increased by 1.9% on a constant currency basis.</li><li>Adjusted earnings per share grew by 1.7%, despite being offset by reductions in ITC profits and higher finance costs.</li></ul>

British American Tobacco (BAT) presented their 2025 interim results, showing a blend of achievements and challenges that influence the company's future trajectory.BAT's revenue rose by 1.8%, and profits from operations increased by 1.9% on a constant currency basis.Adjusted earnings per share grew by 1.7%, despite being offset by reductions in ITC profits and higher finance costs.

British American Tobacco’s Velo Plus Shakes Up the U.S. – Inside the Battle for Oral Nicotine Dominance!

United Kingdom

British American Tobacco is a multinational consumer goods company that manufactures and sells tobacco and nicotine products, including cigarettes, vapour products, heated tobacco, and modern oral products like nicotine pouches. The company offers brands such as Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Vuse, glo, and Velo. It was founded in 1902 and is headquartered in London, United Kingdom.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

British American Tobacco (BTI US)

Pullback Continues $ACWI; Stick With Defensives; More Countries With Improving Price and RS Trends

Pullback Continues $ACWI; Stick With Defensives. We continue to believe a 1- to 4-month pullback/consolidation is ongoing, and would look for an...

Vermilion Research

Insights from Data Mining Technical Publications - Plant Extracts Including from Cannabis

Herbal medicinal and nutraceutical extracts are seen as instruments to maintain health and treat some conditions. Cannabis, in particular, will see...

Pyari Menon

Apple Dominates a Busy Week for Short Sellers

AAPL grabbed the headlines as short interest exploded 130% in a week to 107,942 shares. Energy names BP and BTI also drew heavy short...

ORTEX Market Intel

ITC - Is It Time for Contrarian Investors to Enter?

ITC's share prices plummeted after a significant tax hike on cigarettes in Jan. Historically, business has been resilient despite hikes + we feel...

Himanshu Dugar

British American Tobacco’s Velo Plus Shakes Up the U.S. – Inside the Battle for Oral Nicotine Dominance!

British American Tobacco (BAT) presented their 2025 interim results, showing a blend of achievements and challenges that influence the company's...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Pullback Continues $ACWI; Stick With Defensives; More Countries With Improving Price and RS Trends

Pullback Continues $ACWI; Stick With Defensives. We continue to believe a 1- to 4-month pullback/consolidation is ongoing, and would look for an...

Vermilion Research

Insights from Data Mining Technical Publications - Plant Extracts Including from Cannabis

Herbal medicinal and nutraceutical extracts are seen as instruments to maintain health and treat some conditions. Cannabis, in particular, will see...

Pyari Menon

Apple Dominates a Busy Week for Short Sellers

AAPL grabbed the headlines as short interest exploded 130% in a week to 107,942 shares. Energy names BP and BTI also drew heavy short...

ORTEX Market Intel

ITC - Is It Time for Contrarian Investors to Enter?

​ITC's share prices plummeted after a significant tax hike on cigarettes in Jan. Historically, business has been resilient despite hikes + we feel...

Himanshu Dugar

British American Tobacco’s Velo Plus Shakes Up the U.S. – Inside the Battle for Oral Nicotine Dominance!

British American Tobacco (BAT) presented their 2025 interim results, showing a blend of achievements and challenges that influence the company's...

Baptista Research

ITC's share prices plummeted after a significant tax hike on cigarettes in Jan. Historically, business has been resilient despite hikes + we feel...